---
title: NIC-ASA and ICSA Midwest Chapter Joint Fall Meeting
author: ''
date: '2021-10-22T06:00:00-07:00'
slug: nic-asa-and-icsa-midwest-chapter-joint-fall-meeting
categories: []
tags: []
type: conference
url_freeregister: https://www.eventbrite.com/e/nic-asa-and-icsa-midwest-chapter-joint-fall-meeting-tickets-178365595297
url_slides: ~
url_code: ~
url_pdf: ~
url_video: https://community.amstat.org/northeasternillinoischapter/events/past-events
url_website: https://community.amstat.org/northeasternillinoischapter/home
url_agenda: ~
location: ~
address:
  street: ~
  city: ~
  region: ~
  postcode: ~
  country: ~
date_end: '2021-10-22T14:00:00-07:00'
all_day: no
publishDate: '2021-10-26T13:59:26-07:00'
authors: []
featured: no
image:
  caption: ''
  focal_point: ''
  preview_only: no
slides: ''
projects: []
summary: ~
abstract: ~
---

<!--more-->
Agenda and Program is as follows:  

**8:00 to 8:10**   Opening Remarks, Li Wang from AbbVie and James Myles from Astellas  
  
**8:10 to 9:10**   Keynote Speaker: Dr. Yaning Wang, former Director of Division of Pharmacometrics, Center for Drug Evaluation and Research, FDA, Current CEO of Lang Lai Pharma (45 mins, 15 mins Q&A)
 "Misconceptions and Facts about Aducanumab Approval"      
   
**9:10 – 9:15 break**  
  
**9:15 to 10:45 Session 1, Lung Transplant Real-World Evidence Submission: A Case Study** 
  
Speakers:     
- Astellas: Richard Croy, David Nimke, Josie Wolfram  
- Chronic Disease Research Group: Tim Weaver  
- FDA: Taehyun (Ryan) Jung   
 
**10:45 – 10:50 break**  
   
**10:50 – 12:20pm Session 2, Machine Learning Methods for Risk Prediction**  
  
"Leveraging longitudinal and multi-modal EHR in Clinical Predictions" Yifan Peng (Cornell University)  
  
"Comparison of the State-of-the-Art Neural Network Survival Models and Pooled Cohort Equations on Cardiovascular Disease Risk Prediction" Yu Deng (Northwestern University)   
  
"Deep Neural Network with a Smooth Monotonic Output Layer for Dynamic Risk Prediction" Zhiyang Zhou (University of Manitoba)  
  
**12:20 to 1pm Lunch**  
  
**1:00 to 2:30pm Session 3, Innovative Trial Designs**   
BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies Ying Yuan (University of Texas MD Anderson Cancer Center)   

Simultaneous False-Regulatory Error Rates in Master Protocols with Shared Control: False Discovery Rate Perspective. Jingjing Ye (BeiGene)  

Practical Response Adaptive Randomization Designs with Efficient Inference Procedures Tianyu Zhan (AbbVie)  

**2:30pm – 2:35pm**

**2:35pm – 4:05pm Session 4, Innovative Design and Analysis for Time to Event Trials**  

"Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades" Qing Xia  (University of Kansas Medical Center)   
  
"Handling Death as an Intercurrent Event in Time to Recovery Analysis in COVID-19 Treatment Clinical Trials" Hong Li (AbbVie)  
  
"Bayesian Interim Decision Strategy in Phase III Time-To-Event Study" David Ipe (AbbVie)  
  
**4:05pm – 4:10pm Closing Remark**
  